Cardiff Oncology Inc (CRDF) News & EventsCRDFNews & EventsCardiff Oncology Inc

Cardiff Oncology Announces Results from CRDF-004 Clinical Trial

Cardiff Oncology announced results from CRDF-004, a randomized, controlled, dose-finding Phase 2 clinical trial evaluating onvansertib in combination with SoC regimens in patients with first-line RAS-mutated metastatic colorectal cancer. Results showed that the selected dose/regimen of the registrational program, onvansertib 30 mg + FOLFIRI/bev, demonstrated deep and durable tumor shrinkage, including clinically meaningful improvements in overall response rate and progression-free survival compared to SoC alone, with no additive adverse events. The data were presented at the 2026 American Society of Clinical Oncology, or ASCO, annual meeting in Chicago. Following the completion of the End-of-Phase 2 meeting with the FDA, the company has aligned on the design of the registrational trial with onvansertib in mCRC. The randomized, controlled Phase 3 trial will evaluate the safety and efficacy of onvansertib 30 mg + FOLFIRI/bev as first-line therapy versus standard-of-care FOLFIRI/bev in patients with RAS-mutated mCRC. In the intent-to-treat population, the dose selected for the registrational program, 30 mg onvansertib arm in combination with FOLFIRI/ bev achieved. Primary endpoint of confirmed objective response rate of 72.2%, compared with 42.1% for FOLFIRI/bev alone, a 30% improvement over standard-of-care. The responses were deeper and more durable in the onvansertib arm. Secondary endpoint of progression free survival hazard ratio of 0.55 and 0.57 vs. FOLFIRI/bev by Blinded Independent Central Review and investigator assessment, respectively. Median PFS not reached in 30 mg onvansertib + FOLFIRI/bev arm, but has been reached in both SoC arms. Four patients remain on onvansertib treatment beyond 15 months, including 2 beyond 20 months. Notably, fourteen patients remain on trial, with nine patients in the onvansertib plus FOLFIRI/bev arms and one patient remaining on SoC. No meaningful differences in efficacy were observed between the onvansertib + FOLFOX/bev arms and FOLFOX/bev alone. Onvansertib in combination with both chemotherapy FOLFIRI or FOLFOX/bev regimens was well-tolerated. There were no major or unexpected toxicities observed and no additive adverse events reported. Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event across both the onvansertib combination and SoC arms.

Lifevantage Borrow Rate Increases to 271.40%

Latest data shows the largest indicative borrow rate increases among liquid option names include: Lifevantage (LFVN) 271.40% +6.04, Deutsche Bank (DB) 13.28% +1.84, Cardiff Oncology (CRDF) 12.68% +1.74, Ericsson (ERIC) 2.45% +1.16, Tradr 2X Short SNDK Daily ETF (SNDQ) 30.73% +1.10, JEPQ (JEPQ) 2.19% +1.06, Infosys (INFY) 24.51% +0.79, Critical Metals Corp (CRML) 28.36% +0.53, Red Cat Holdings (RCAT) 1.23% +0.43, and Applix Inc. (APLX) 13.71% +0.35.